A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity
暂无分享,去创建一个
T. Breugelmans | P. Jorens | B. Loeys | L. Heyndrickx | S. Kumar-Singh | S. Coenen | K. Ariën | R. Jacobs | B. D. De Winter | S. Malhotra-Kumar | A. Hotterbeekx | A. Smet | J. D. De Man | M. Huizing | J. Míchiels | M. Lammens | K. Lamote | V. Verhoeven | A. Verstraeten | K. Dams | W. Arras | Anne Hauner
[1] D. Bennett,et al. Serial KL-6 measurements in COVID-19 patients , 2021, Internal and Emergency Medicine.
[2] P. Brodin. Immune determinants of COVID-19 disease presentation and severity , 2021, Nature Medicine.
[3] P. Mukherjee,et al. Mucin signature as a potential tool to predict susceptibility to COVID‐19 , 2020, Physiological reports.
[4] S. Cosgrove,et al. Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study , 2020, Open forum infectious diseases.
[5] Cameron R. Wolfe,et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 , 2020, The New England journal of medicine.
[6] P. Verweij,et al. Fungal infections should be part of the core outcome set for COVID-19 , 2020, The Lancet Infectious Diseases.
[7] Y. Dou,et al. Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses , 2020, Computational and Structural Biotechnology Journal.
[8] A. Farcomeni,et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality , 2020, Science Advances.
[9] C. Qin,et al. Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19 , 2020, Cell Research.
[10] Eric A. Meyerowitz,et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.
[11] B. Weynand,et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity , 2020, Proceedings of the National Academy of Sciences.
[12] S. Farhadian,et al. Sex differences in immune responses that underlie COVID-19 disease outcomes , 2020, Nature.
[13] I. Bassett,et al. Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses , 2020, The Journal of Pediatrics.
[14] J. Mason,et al. A dynamic COVID-19 immune signature includes associations with poor prognosis , 2020, Nature Medicine.
[15] Fei Liu,et al. Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID‐19 patients , 2020, Journal of medical virology.
[16] Shu-Yan Liu,et al. Mucin mutations and aberrant expression are associated with the pathogenesis of immune thrombocytopenia. , 2020, Thrombosis research.
[17] Xi He,et al. Single-cell analysis reveals bronchoalveolar epithelial dysfunction in COVID-19 patients , 2020, Protein & Cell.
[18] C. von Kalle,et al. COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.
[19] Adam C. Labonte,et al. Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway , 2020, Scientific Reports.
[20] S. Rose-John,et al. Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells , 2020, PloS one.
[21] S. Ruan. Likelihood of survival of coronavirus disease 2019 , 2020, The Lancet Infectious Diseases.
[22] Xavier Duval,et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series , 2020, The Lancet Infectious Diseases.
[23] W. Triampo,et al. The Blood Circulating Rare Cell Population. What Is It and What Is It Good for? , 2020, Cells.
[24] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[25] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[26] T. Breugelmans,et al. In depth study of transmembrane mucins in association with intestinal barrier dysfunction during the course of T cell transfer and DSS-induced colitis. , 2020, Journal of Crohn's & colitis.
[27] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[28] E. Mao,et al. Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-κB pathway , 2019, Drug design, development and therapy.
[29] Yoshiya Tanaka,et al. Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System , 2018, Front. Immunol..
[30] Markus M. Rinschen,et al. Autosomal Tubulointerstitial Kidney Disease—MUC1 Type: Differential Proteomics Suggests that Mutated MUC1 (insC) Affects Vesicular Transport in Renal Epithelial Cells , 2018, Proteomics.
[31] E. Lillehoj,et al. MUC1: The First Respiratory Mucin with an Anti-Inflammatory Function , 2017, Journal of clinical medicine.
[32] N. Udagawa,et al. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro , 2017, PloS one.
[33] C. Liu,et al. Gastric De Novo Muc13 Expression and Spasmolytic Polypeptide-Expressing Metaplasia during Helicobacter heilmannii Infection , 2014, Infection and Immunity.
[34] E. Hachulla,et al. Effect of In Vitro and In Vivo Anakinra on Cytokines Production in Schnitzler Syndrome , 2013, PloS one.
[35] S. Pereson,et al. Cellular ageing, increased mortality and FTLD‐TDP‐associated neuropathology in progranulin knockout mice , 2012, The Journal of pathology.
[36] K. Pantel,et al. Circulating epithelial cells in patients with benign colon diseases. , 2012, Clinical chemistry.
[37] D. Kufe,et al. Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.
[38] Mark M Davis,et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device , 2009, Proceedings of the National Academy of Sciences.
[39] P. Friedman,et al. Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells , 2008, Journal of hematology & oncology.
[40] N. Kohno,et al. Circulating KL‐6/MUC1 as an independent predictor for disseminated intravascular coagulation in acute respiratory distress syndrome , 2008, Journal of internal medicine.
[41] V. Korolik,et al. Mucins in the mucosal barrier to infection , 2008, Mucosal Immunology.
[42] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Bulletin of the World Health Organization.
[43] S. Pocock,et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, BMJ : British Medical Journal.
[44] Gerd Schmitz,et al. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease , 2006, Journal of Molecular Medicine.
[45] Stephen Tomlinson,et al. The effect of dexamethasone on human mucin 1 expression and antibody‐dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo , 2004, Immunology.
[46] J. Taylor‐Papadimitriou,et al. Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T‐cell migration , 2003, Immunology.
[47] G. Sutherland,et al. MUC13, a Novel Human Cell Surface Mucin Expressed by Epithelial and Hemopoietic Cells* , 2001, The Journal of Biological Chemistry.
[48] J. Vincent,et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.
[49] Arthur S Slutsky,et al. Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .
[50] M. Conrad,et al. A role for mucin in the absorption of inorganic iron and other metal cations. A study in rats. , 1991, Gastroenterology.